Scarica l'app Stockscreener
1.92
4.92%
0.09
Dopo l'orario di chiusura:
1.91
-0.01
-0.52%
Precedente Chiudi:
$1.83
Aprire:
$1.8027
Volume 24 ore:
63,155
Relative Volume:
2.09
Capitalizzazione di mercato:
$1.16M
Reddito:
$598.00K
Utile/perdita netta:
$-44.93M
Rapporto P/E:
-0.231
EPS:
-8.31
Flusso di cassa netto:
$-17.32M
1 W Prestazione:
+5.49%
1M Prestazione:
-28.89%
6M Prestazione:
-60.41%
1 anno Prestazione:
-92.93%
Intervallo 1D:
$1.8027
$2.00
Intervallo di 1 settimana:
$1.8027
$2.13
Portata 52W:
$1.75
$39.38
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Nome
Ernexa Therapeutics Inc
Settore
Industria
Telefono
(617) 798-6700
Indirizzo
1035 CAMBRIDGE STREET, CAMBRIDGE
Confronta ERNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
1.92 | 1.16M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.36 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.75 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.50 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
538.64 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.47 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ernexa Therapeutics Inc Borsa (ERNA) Ultime notizie
Ernexa Therapeutics (NASDAQ:ERNA) Shares Up 5.9% – What’s Next? - Defense World
Sector Update: Health Care - MarketScreener
Ernexa Therapeutics Shares Fall Pre-Bell Following Reverse Stock Split - marketscreener.com
Ernexa Therapeutics stock plummets on announcing 1-for-15 reverse stock split - MSN
Ernexa Therapeutics announces 1-for-15 reverse stock split By Investing.com - Investing.com South Africa
Eterna Therapeutics Implements 1-for-15 Reverse Stock Split - TipRanks
Ernexa Therapeutics announces 1-for-15 reverse stock split - Investing.com
Ernexa Therapeutics registers 57M shares for resale - MSN
Ernexa therapeutics ten percent owner acquires $2.22 million in stock By Investing.com - Investing.com Nigeria
Ernexa therapeutics ten percent owner acquires $2.22 million in stock - Investing.com Australia
Eterna Therapeutics Files for Resale of 57 Million Shares - marketscreener.com
Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance - Nasdaq
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split - citybiz
Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish - MSN
Ernexa Therapeutics Announces 1-For-15 Reverse Stock Split - marketscreener.com
Ernexa Plans 93% Share Reduction in Critical Nasdaq Compliance Move - Stock Titan
Eterna Therapeutics Completes $6M Private Placement - TipRanks
Eterna Therapeutics Increases Authorized Shares and Amends Bylaws - TipRanks
Ernexa Therapeutics announces new data to be presented at ASCO meeting 2025 - TipRanks
Ernexa Therapeutics to Present Breakthrough Data on iMSC-Based Immunotherapy at ASCO Annual Meeting 2025 - Nasdaq
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 - GlobeNewswire
Ernexa Therapeutics Establishes Texas Subsidiary to Support - GlobeNewswire
Ernexa's New Texas Hub Accelerates Novel Ovarian Cancer Treatment: MD Anderson Expert Leads Research - Stock Titan
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
ERNAErnexa Latest Stock News & Market Updates - Stock Titan
Can Ernexa Crack Ovarian Cancer with Novel Stem Cell Approach? - Inside Precision Medicine
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 - GlobeNewswire
Revolutionary Stem Cell Therapy Fights Cancer in Two Ways, MD Anderson Study Shows - Stock Titan
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 - The Manila Times
Revolutionary Tumor-Fighting Cell Therapy: MD Anderson to Present Ernexa's Ovarian Cancer Breakthrough at AACR - Stock Titan
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
Ernexa Therapeutics Inc Files Prospectus For Resale Of 10.4 Million Shares Of Common Stock By Selling Stockholder- SEC Filing - marketscreener.com
Smart Trial Design In Cell Therapy: Fast-Tracking Without Compromising - Clinical Leader
Eterna therapeutics sees $394,174 stock acquisition by Charles Cherington - Investing.com Australia
ERNA stock touches 52-week low at $0.16 amid sharp annual decline - Investing.com India
Ernexa Therapeutics Closes New Funding Round - GlobeNewswire
Biotech Breakthrough: Ernexa Secures $7.25M to Advance Revolutionary Cancer Treatment - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com
Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire
Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
Ernexa Therapeutics Inc Azioni (ERNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ernexa Therapeutics Inc Azioni (ERNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Apr 02 '25 |
Buy |
0.10 |
3,768,397 |
394,174 |
20,401,602 |
3.56%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):